Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Active Systemic Lupus Erythematosus Clinical Trial

Official title:

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02446899
• Other study ID #: D3461C00004
• Status: Completed
• Phase: Phase 3
• Start date: July 9, 2015
• Est. completion date: September 27, 2018

Study information

• Verified date: December 2022
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Description:

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. The study will be performed in adult participants aged 18 to 70 years of age.

Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed intravenous dose of anifrolumab 300 mg or placebo every 4 weeks for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous infusion (IV) via an infusion pump over a minimum of 30 minutes, every 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 373
• Est. completion date: September 27, 2018
• Est. primary completion date: September 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged 18 through 70 years at the time of screening

2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982 revised criteria =24 weeks prior to signing the Informed Consent form (ICF)

3. Currently receiving at least 1 of the following:

1. Where prednisone is the single standard of care medication (ie, the subject is not concurrently receiving any medication listed in inclusion criterion 3(c)), a dose of oral prednisone =7.5 mg/day but =40 mg/day (or prednisone equivalent) for a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation

2. Where prednisone is not the single standard of care medication (ie, the subject is concurrently receiving at least one medication listed in inclusion criterion 3(c), a dose of oral prednisone (=40 mg/day) (or prednisone equivalent) for a minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral prednisone or prednisone equivalent the subject is taking must be stable for a minimum of 2 weeks prior to randomisation.

3. Any of the following medications administered for a minimum of 12 weeks prior to signing the informed consent, and at a stable dose for a minimum of 8 weeks prior to signing the informed consent and through Day 1:

(i) Azathioprine =200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate =25 mg/week (v) Mizoribine =150 mg/day

4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:

1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay (IFA) at the central laboratory with titre =1:80; OR

2. Anti-dsDNA antibodies at screening elevated to above normal (including indeterminate), as per the central laboratory; OR

3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the central laboratory

5. At Screening, Disease Activity Adjudication Group confirmation of:

SLEDAI-2K Criteria: SLEDAI-2K score =6 points and "Clinical" SLEDAI-2K score =4 points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.

6. Must not have active or latent TB on either chest radiograph or by quantiferon gold test

7. Day 1 "Clinical" SLEDAI-2K score =4 points

8. OCS dose stable for at least 2 weeks prior to randomisation

9. Stable SLE SOC treatment at the time of randomisation

10. Women of child-bearing potential must have a negative serum ß-hCG test at and negative urine pregnancy test at randomisation prior to administration of investigational product

Exclusion Criteria:

1. Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater

2. Receipt of any of the following:

(a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1

3. History of, or current diagnosis of, a clinically significant non SLE-related vasculitis syndrome.

4. Active severe or unstable neuropsychiatric SLE

5. Active severe SLE-driven renal disease

6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE or SSc.

7. History of, or current, inflammatory joint or skin disease other than SLE

8. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the ICF

9. 26.27. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation

10. Confirmed positive test for hepatitis B or hepatitis C

11. Any severe herpes infection at any time prior to Week 0 (Day 1)

12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial treatment within 3 years prior to randomization

13. History of cancer, apart from:

1. Squamous or basal cell carcinoma of the skin that has been successfully treated

2. Cervical cancer in situ that has been successfully treated

Related Conditions & MeSH terms

• Active Systemic Lupus Erythematosus
• Lupus Erythematosus, Systemic

Intervention

Biological:
• Anifrolumab
Intravenous infusion (IV)

Drug:
• Placebo
Intravenous infusion (IV)

Locations

Country	Name	City	State
Argentina	Research Site	Buenos Aires
Argentina	Research Site	Mendoza
Argentina	Research Site	Quilmes
Belgium	Research Site	Bruxelles
Belgium	Research Site	Leuven
Belgium	Research Site	Liege
Belgium	Research Site	Merksem
Brazil	Research Site	Goiania
Brazil	Research Site	Juiz de Fora
Brazil	Research Site	Sao Paulo
Brazil	Research Site	Sao Paulo
Brazil	Research Site	Sao Paulo
Bulgaria	Research Site	Plovdiv
Bulgaria	Research Site	Plovdiv
Canada	Research Site	Hamilton	Ontario
Canada	Research Site	Rimouski	Quebec
France	Research Site	Bordeaux
France	Research Site	Lille
France	Research Site	Montpellier CEDEX 5
France	Research Site	Paris
France	Research Site	Paris
France	Research Site	Pessac
France	Research Site	Toulouse
Germany	Research Site	Berlin
Germany	Research Site	Hamburg
Germany	Research Site	Jena
Germany	Research Site	Mainz
Germany	Research Site	München
Japan	Research Site	Chiba-shi
Japan	Research Site	Chuo-ku
Japan	Research Site	Fukuoka-shi
Japan	Research Site	Fukuoka-shi
Japan	Research Site	Hiroshima-shi
Japan	Research Site	Kitakyushu-shi
Japan	Research Site	Kurashiki-shi
Japan	Research Site	Meguro-ku
Japan	Research Site	Meguro-ku
Japan	Research Site	Nagasaki-shi
Japan	Research Site	Nagoya-shi
Japan	Research Site	Omura-shi
Japan	Research Site	Sapporo-shi
Japan	Research Site	Sasebo-shi
Japan	Research Site	Sendai-shi
Japan	Research Site	Shinjuku-ku
Japan	Research Site	Tsukuba
Korea, Republic of	Research Site	Jeju-si
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Suwon-si
Lithuania	Research Site	Kaunas
Lithuania	Research Site	Klaipeda
Mexico	Research Site	Chihuahua
Mexico	Research Site	Leon
Mexico	Research Site	Mérida
Mexico	Research Site	Mexico
Mexico	Research Site	Mexico D.F.
Mexico	Research Site	Morelia
Mexico	Research Site	San Luis Potosí
Russian Federation	Research Site	Kemerovo
Russian Federation	Research Site	Petrozavodsk
Russian Federation	Research Site	Smolensk
Russian Federation	Research Site	Tolyatti
Russian Federation	Research Site	Vladimir
Russian Federation	Research Site	Yaroslavl
South Africa	Research Site	Cape Town
South Africa	Research Site	Johannesburg
South Africa	Research Site	Johannesburg
South Africa	Research Site	Stellenbosch
Spain	Research Site	Barcelona
Spain	Research Site	Getafe
Spain	Research Site	Las Palmas de Gran Canaria
Spain	Research Site	Madrid
Spain	Research Site	Madrid
Spain	Research Site	Mérida
Spain	Research Site	Santiago de Compostela
Spain	Research Site	Servilla
Spain	Research Site	Vigo
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Arlington	Virginia
United States	Research Site	Atlanta	Georgia
United States	Research Site	Boston	Massachusetts
United States	Research Site	Brandon	Florida
United States	Research Site	Bridgeport	Connecticut
United States	Research Site	Bridgeport	Connecticut
United States	Research Site	Brooklyn	New York
United States	Research Site	Covina	California
United States	Research Site	Dallas	Texas
United States	Research Site	Denver	Colorado
United States	Research Site	Duncansville	Pennsylvania
United States	Research Site	Greenville	North Carolina
United States	Research Site	Hemet	California
United States	Research Site	Houston	Texas
United States	Research Site	Houston	Texas
United States	Research Site	Las Cruces	New Mexico
United States	Research Site	Lincoln	Nebraska
United States	Research Site	Los Angeles	California
United States	Research Site	Memphis	Tennessee
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	Oklahoma City	Oklahoma
United States	Research Site	Orlando	Florida
United States	Research Site	Palm Harbor	Florida
United States	Research Site	Pittsburgh	Pennsylvania
United States	Research Site	San Leandro	California
United States	Research Site	Seattle	Washington
United States	Research Site	Spokane	Washington
United States	Research Site	Stafford	Texas
United States	Research Site	Tamarac	Florida
United States	Research Site	Tampa	Florida
United States	Research Site	Torrance	California
United States	Research Site	Upland	California

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	PRA Health Sciences

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Brazil,  Bulgaria,  Canada,  France,  Germany,  Japan,  Korea, Republic of,  Lithuania,  Mexico,  Russian Federation,  South Africa,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52	Composite endpoint BICLA was defined by meeting all of the following criteria: Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by =1 new BILAG-2004 A or =2 new BILAG-2004 B; No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of >0 points in SLEDAI-2K; No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase =0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS); No discontinuation of investigational product; No use of restricted medications beyond the protocol allowed threshold before assessment	Baseline; Week 52
Secondary	Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group	Defined by meeting all of the following criteria: Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by =1 new BILAG-2004 A or =2 new BILAG-2004 B; No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to >0 points in SLEDAI-2K; No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase =0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS); No discontinuation of investigational product; No use of restricted medications beyond the protocol allowed threshold before assessment	Baseline; Week 52
Secondary	Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of =7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS =10 mg/Day	Maintained OCS reduction was defined by meeting all of the following criteria: Achieve an OCS dose of =7.5 mg/day prednisone or equivalent by Week 40; Maintain an OCS dose =7.5 mg/day prednisone or equivalent from Week 40 to Week 52; No discontinuation of investigational product; No use of restricted medications beyond the protocol allowed threshold before assessment	Week 40; Week 52
Secondary	Number of Participants With a =50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of =10	50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria: Achieve =50% reduction of CLASI activity score at Week 12 compared to baseline; No discontinuation of investigational product; No use of restricted medications beyond the protocol allowed threshold before assessment	Baseline; Week 12
Secondary	Number of Participants With =50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With =6 Swollen and =6 Tender Joints at Baseline	50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria: Achieve =50% reduction from baseline in the number of swollen and tender joints, separately; No discontinuation of investigational product; No use of restricted medications beyond the protocol allowed threshold before assessment	Baseline; Week 52
Secondary	Annualised Flare Rate Through 52 Weeks	A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.	Baseline to Week 52
Secondary	Number of Participants With One or More Adverse Events (AEs)	An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.	Baseline to end of study (Maximum of 60 weeks)
Secondary	Number of Participants With One or More Adverse Events of Special Interest (AESIs)	An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus [SLE]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction [MI], or cardiovascular death).; AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).	Baseline to end of study (Maximum of 60 weeks)
Secondary	Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements	Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.; Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).	Baseline to end of study (Maximum of 60 weeks)
Secondary	Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests	Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests.; Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).	Baseline to end of study (Maximum of 60 weeks)

External Links

•   Redacted CSP
•   Redacted SAP